|Bid||108.52 x 800|
|Ask||116.25 x 800|
|Day's Range||112.22 - 116.74|
|52 Week Range||47.78 - 116.74|
|Beta (3Y Monthly)||2.38|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the […]
Exact Sciences Corp NASDAQ:EXASView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for EXAS with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EXAS had net inflows of $1.92 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Wendys Co (NASDAQ: WEN ) is one of his absolute favorites. Cramer is a buyer of Zoetis Inc (NYSE: ZTS ). He added that the stock hit another ...
We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.
Exact Sciences Corporation's (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on...
Exact Sciences Corp., the Madison-based maker of the Cologuard take-home colon cancer test and one of the largest public companies in Wisconsin, is reportedly returning $61,000 it received from the Wisconsin Economic Development Corp. because a certain number of jobs the money was intended for were created outside of Wisconsin. In 2015, Exact Sciences was approved by the WEDC to receive up to $9 million in tax credits if it added at least 750 jobs and made a capital investment of $26 million by 2020. Under the agreement, Exact Sciences would receive the WEDC tax incentives by investing in capital expenditures in Wisconsin and creating 758 new full-time positions – with an average wage of $24.47 per hour – in the state by Dec. 31, 2020.
Sometimes the U.S. stock market sends a clear, unambiguous message. The message the stock market sent during Federal Reserve Chairman Jerome Powell’s press conference Wednesday says that the market is vulnerable. • The chart shows that the stock market rose immediately after the Fed decision was announced.
The maker of the Cologuard colorectal cancer screening test reported tremendous revenue growth -- but a worsening bottom line.
The Madison, Wisconsin-based company said it had a loss of 66 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
The company raised its guidance for its fiscal 2019, anticipating revenues between $725 million and $740 million.
As a record-breaking economic expansion nears the decade mark, people like Marty Groth may determine whether it is forced into a lower gear. Not long ago, the 60-year-old Groth found himself out of a job and considered retiring on a pension built over a career of maintaining computer servers and printers. Instead, he returned to school to update his computer skills and will soon join a Wisconsin labour force that is decidedly short of workers.
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.